Tryon Williams
Chairman at KIDOZ INC.
Net worth: 3 M $ as of 2024-06-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jason Williams | M | 49 | 23 years | |
Eldad Tora | M | 54 | 11 years | |
Henry Bromley | M | 53 | 22 years | |
Fiona Curtis | F | 58 | 15 years | |
Claes Kalborg | M | 62 | 6 years | |
Moshe David | M | 59 | 5 years | |
Lee Groat | M | - |
University of British Columbia
| 21 years |
Neil Cashman | M | 72 |
University of British Columbia
| 19 years |
Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 years |
Michael Hitch | M | - |
University of British Columbia
| 17 years |
Daniel Pauly | M | - |
University of British Columbia
| 30 years |
Kevin McElwee | M | 54 |
University of British Columbia
| 20 years |
R. Scott McKinley | M | 68 |
University of British Columbia
| 23 years |
Steven Plotkin | M | - |
University of British Columbia
| 23 years |
David M. Liu | M | 50 |
University of British Columbia
| 16 years |
Tryon Williams | M | 53 | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nick Glover | M | 55 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
Leonard Vernon | M | 80 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Ebba Dagmar Lucie Ljungerud | F | 52 | 4 years | |
Helge Seetzen | M | - |
University of British Columbia
| 11 years |
Paul Thomas | M | 50 |
University of British Columbia
| 3 years |
Farzad Forooghian | M | 45 |
University of British Columbia
| 4 years |
Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
David Phillips | M | - |
University of British Columbia
| 4 years |
Steve Veitch | M | - |
University of British Columbia
| 5 years |
Ali Kashani | M | 39 |
University of British Columbia
| 3 years |
Derek Hemmes | M | - |
University of British Columbia
| 10 years |
Peeyush Varshney | M | 57 |
University of British Columbia
| 8 years |
Vanessa Collette | F | - |
University of British Columbia
| 5 years |
Johan Petter Erik Nylander | M | 60 | 1 years | |
Akio Tanaka | M | 54 |
University of British Columbia
| 6 years |
Mouane Sengsavang | F | 47 |
University of British Columbia
| 8 years |
James Smith | M | 54 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
Jeff Hunter | M | - |
University of British Columbia
| 6 years |
Li Zhu | F | - |
University of British Columbia
| 3 years |
Wen Chuan Zhou | F | 40 |
University of British Columbia
| 5 years |
Wale Bolorunduro | M | - |
University of British Columbia
| 4 years |
Wen Wei Guan | M | 55 |
University of British Columbia
| 5 years |
Kong Lok Yip | M | 48 |
University of British Columbia
| 5 years |
Michael Leo | M | 47 |
University of British Columbia
| 6 years |
Gabriel Fung | M | - |
University of British Columbia
| 7 years |
Vladimir Cvijetinovic | M | - |
University of British Columbia
| 7 years |
Hon Sum Sam Jor | M | 42 |
University of British Columbia
| 5 years |
Frank S. Moyle | M | - |
University of British Columbia
| 9 years |
Persio Pellegrini Rosario | M | - |
University of British Columbia
| 5 years |
Ben De Wit | M | - |
University of British Columbia
| 7 years |
Dong Xiao Qiu | M | 62 |
University of British Columbia
| 5 years |
Salim Dhanji | M | 44 |
University of British Columbia
| 8 years |
John Priatel | M | 58 |
University of British Columbia
| 11 years |
Nick B. Drake | M | - |
University of British Columbia
| 10 years |
Sebastian Jaimungal | M | - |
University of British Columbia
| 5 years |
Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 years |
Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
George Whitton | M | 86 | - | |
Amanda Gale Miller | F | 42 |
University of British Columbia
| 8 years |
Jacqueline Simpson | F | - |
University of British Columbia
| 11 years |
Robert E. Cohen | M | - |
University of British Columbia
| 11 years |
Thomas Ian Alexander Allen | M | 83 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Roger Quick | M | - |
University of British Columbia
| 7 years |
Henry Friesen | M | 90 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Hans Knapp | M | - |
University of British Columbia
| 3 years |
Arsalan Farrokh | M | - |
University of British Columbia
| 4 years |
Claire Huxtable | F | - |
University of British Columbia
| 6 years |
Shaun Foy | M | - |
University of British Columbia
| 9 years |
François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
Trevor Robinson | M | - |
University of British Columbia
| 18 years |
Christopher Mark Devereux | M | 59 | 16 years | |
Mark Kowalski | M | 69 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Matthew Hamilton | M | 41 |
University of British Columbia
| 5 years |
Arie Page | F | 45 |
University of British Columbia
| 8 years |
Jonathan Bey | M | 54 |
University of British Columbia
| 5 years |
Lei Huang | F | 41 |
University of British Columbia
| 4 years |
Leonardo Viana Nicacio | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
Michael Minor | M | - |
University of British Columbia
| 4 years |
Jim Chan | M | - |
University of British Columbia
| 4 years |
Asha Reeves | F | 52 |
University of British Columbia
| 4 years |
Kristina Hess | F | - |
University of British Columbia
| 4 years |
Rajeena Minhas | F | - |
University of British Columbia
| 4 years |
Wendi V. Rodrigueza | M | 58 |
University of British Columbia
| 3 years |
Adrian Crawford Ansell | M | 65 |
University of British Columbia
| 5 years |
John Edward Veltheer | M | 58 |
University of British Columbia
| 3 years |
Nousheen Huq | F | 53 |
University of British Columbia
| 3 years |
Glans Graydon | M | 37 |
University of British Columbia
| 4 years |
Keith Gillard | M | - |
University of British Columbia
| 5 years |
Ryan Weymark | M | - |
University of British Columbia
| 4 years |
Yao Yao | M | 35 |
University of British Columbia
| 4 years |
Rory Edward North | M | - |
University of British Columbia
| 4 years |
Ross Smith | M | 85 |
University of British Columbia
| 6 years |
Brad Peters | M | 51 |
University of British Columbia
| 4 years |
Michael Shaw | M | - |
University of British Columbia
| 4 years |
Alvin Cheung | M | - |
University of British Columbia
| 5 years |
Michael Leung | M | - |
University of British Columbia
| 4 years |
Colin I. Godwin | M | 84 |
University of British Columbia
| 24 years |
Chadwick Wasilenkoff | M | - |
University of British Columbia
| 4 years |
Kevin Cohen | M | - |
University of British Columbia
| 3 years |
Abdul Farooqi | M | - |
University of British Columbia
| 4 years |
Wendy Louise Bach | F | 69 |
University of British Columbia
| 3 years |
Randy Smallwood | M | 59 |
University of British Columbia
| 4 years |
Jason Ng | M | - |
University of British Columbia
| 4 years |
Paul McMillan | M | - |
University of British Columbia
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 89 | 89.00% |
United Kingdom | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Tryon Williams
- Personal Network